Eris Lifesciences Launches Generic Semaglutide Under Brand 'SUNDAE' in India, Starting at ₹220 Per Shot

Eris Lifesciences, a leading Indian branded formulations company, has announced the launch of its generic Semaglutide under the brand 'SUNDAE' in India. The product is launched in multi-dose vial formats at highly accessible pricing starting at Rs 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants. This launch significantly improves affordability, bringing effective GLP-1 therapy within reach for nearly 70% of India’s diabetes patient population. The company also plans to introduce a pen-device version in April priced at MRP of INR 4,000, INR 4,200 and INR 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively. Semaglutide, a GLP-1 receptor agonist, has emerged as a transformative therapy for Type 2 diabetes and weight management.